33 results about "Polymyositis" patented technology

This invention relates to one anti-extracting nuclear antigen spectrum array to ELISA test agent case for selecting for systematic lupus erythematosus, mixed connective tissue disease, Sjogren syndrome, systemic scleroderma, polymyositis and atrophic arthritis system self immune property antigen ENA spectrum micro array to enzyme immune agent case.

There is disclosed a method of treating various diseases caused by micro-vasculature circulation problems, including, but not limited to, vascular insufficiency, phantom pain, diabetic neuropathy, neuropathic pain, autoimmune/inflammatory diseases (e.g., multiple sclerosis, Parkinson's disease, Crohn's Disease, lupus, rheumatoid arthritis, polymyalgia rheumatica, polymyositis, dermatomyositis, sarcoidosis), urinary retention, lymphoedema, and chronic renal insufficiency. Specifically, there is disclosed a treatment providing an effective amount of an acetyl cholinesterase inhibitor compound (or combination of compounds) to treat one or a plurality of microvasculature diseases.

The invention relates to medical technology field, discloses a glucocorticoid synergist, and is characterized in adopting total ginsenoside as synergist. Its proportions are respectively as following: total ginsenoside 200mg-1200mg and dexamethasone 0.75-187.5mg; total ginsenoside 200mg-1200mg and betamethason 0.75-187.5mg; total ginsenoside 200-1200mg, and prednisone 5-1250mg, total ginsenoside 200-1200mg, and precortisyl 5-1250mg; total ginsenoside 200mg-1200mg, and urbason 4-1000mg; total ginsenoside 200-1200mg, and cortisone 25-6250mg; and total ginsenoside 200-1200mg, and hydrocortisone 20-5000mg.Total ginsenoside as glucocorticoid synergist can be used in the treatment of diseases requiring long term or a large amount of glucocorticoid such as systemic lupus erythematosus, nephrotic syndrome, polymyositis, and rheumatoid arthritis.

The present invention relates to novel urea and thiourea compounds, compositions comprising urea or thiourea compounds, and methods useful for treating and preventing aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, enhancing bile production, enhancing reverse lipid transport, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, modulating C reactive protein, obesity, oxysterol elimination in bile, pancreatitis, Parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease, septicemia, metabolic syndrome disorders (e.g., Syndrome X), a thrombotic disorder, gastrointestinal disease, irritable bowel syndrome (IBS), inflammatory bowel disease (e.g., Crohn's Disease, ulcerative colitis), arthritis (e.g., rheumatoid arthritis, osteoarthritis), autoimmune disease (e.g., systemic lupus erythematosus), scleroderma, ankylosing spondylitis, gout and pseudogout, muscle pain: polymyositis/polymyalgia rheumatica/fibrositis; infection and arthritis, juvenile rheumatoid arthritis, tendonitis, bursitis and other soft tissue rheumatism. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.

A method for prophylaxis or treatment of a mammal, particularly human, at risk for a fibrogenic disorder is disclosed. The compositions and methods of the invention are directed both to treatments for existing fibrogenic disorders and prevention thereof. Such disorders include, but are not limited to, connective tissue diseases, such as scleroderma (or systemic sclerosis), polymyositis, systemic lupus erythematosis and rheumatoid arthristis, and other fibrotic disorders, including liver cirrhosis, keloid formation, interstitial nephritis and pulmonary fibrosis. A therapeutic composition according to the invention includes, as a therapeutic agent, an inhibitor of a collagen promoter in a pharmaceutically acceptable inert carrier vehicle, preferably for local, and particularly topical, application. Exemplary inhibitors include those that interfere with heat shock protein 90 (Hsp 90) chaperone function, e.g., the specific inhibitor geldanamycin or other known Hsp90 inhibitors such as macbecin I and II, herbimycin, radcicol and novobiocin.

The invention relates to a kit for determining an anti-Jo-1 antibody. The kit comprises a first reagent, wherein the first reagent comprises a mixture coupled with biotin. The mixture comprises a Jo-1antigen and a tRNA. According to the kit and the detection method for determining anti-Jo-1 antibody, the invention has the advantages of good stability, high sensitivity, good repeatability and thelike; a detection system can realize random sample loading, freely combination and continuously detecting, and the detection time is greatly reduced that 120 tests can be completed within 1 hour; andoperations are simple and convenient, a full automatic detection is truly realized, and the result deviation caused by the operations is avoided. Compared with a traditional method, the detection result of the invention is consistent in conformity, and the detection rate of a Jo-1 antibody positive in dermatomyositis/polymyositis is increased to 35%-40%, furthermore the positive signal value is increased by 10-20%.

Method for diagnosis of autoimmune diseases of the GSE-type or associated with gluten sensitive enteropathy comprising taking a sample and testing the sample for antibodies against human tissue transglutaminase, tissue-specific transglutaminases, or other transglutaminases. It was found that autoimmune diseases other than celiac disease can be diagnosed and distinguished in this way, notably, dermatitis herpetiformis Duhring, Crohn's disease, Addison's disease, AI hemolytic anemia, AI thrombocytopenic purpura, AI thyroid diseases, atrophic gastritis—pernicious anemia, IgA nephropathy or IgA glomerulonephritis, myasthenia gravis, partial lipodystrophy, polymyositis, primary biliary cirrhosis, primary sclerosing cholangitis, recurrent pericarditis, relapsing polychondritis, rheumatoid arthritis, rheumatism, sarcoidosis, Sjögren's syndrome, SLE, splenic atrophy, type I (insulin-dependent) diabetes mellitus, diabetes mellitus of other types, ulcerative colitis, vasculitis (both systemic and cutaneous), vitiligo as well as autoimmune diseases associated with infertility, increased risk of abortion, or reduced fetal growth.

The invention discloses a traditional Chinese medicine composition for treating polymyositis. The traditional Chinese medicine composition for treating polymyositis comprises, by weight, 18-20 parts of Rhizoma Coptidis, 6-9 parts of Rhizoma Menispermi, 12-15 parts of Cortex Fissistigmatis Bracteolati Radicis, 18-20 parts of herb of laciniate blumea, 11-13 parts of Herba Epimedii, 4-6 parts of Radix Paeoniae Rubra, 5-6 parts of Herba Ephedrae, 9-12 parts of Feculae Bombycis and 3-5 parts of Gomphrena globosa L.. The invention further provides a preparation method of the traditional Chinese medicine composition for treating polymyositis. The traditional Chinese medicine composition for treating polymyositis is simple in formula, remarkably effective in treatment of polymyositis by being as high as 98.5% in total effective rate and less prone to causing relapse after cure, and is lower in treatment cost and less in toxic or side effect than glucocorticoid, thereby being beneficial to health of patients.

The invention discloses application of a vanillic acid glucoside derivative as shown in formula (I) in treatment of a systemic autoimmune disease. Preferably, the systemic autoimmune disease can be selected from systemic lupus erythematosus, rheumatoid arthritis, systemic sclerosis, Sjogren's syndrome, and polymyositis.

The invention relates to the technical field of biology, and particularly provides a Mi-2 recombinant antigen as well as a preparation method and application thereof. The Mi-2 recombinant antigen comprises at least one sequences representing by SEQ ID NO.1, SEQ ID NO.5 or SEQ ID NO.7, and does not contain sequences representing by SEQ ID NO.2 and/or SEQ ID NO.6. The Mi-2 recombinant antigen improves the sensitivity and specificity of Mi-2 antibody detection, is used for Mi-2 antibody detection or polymyositis diagnosis, can greatly improve the accuracy, and provides a new technical support forproduction and application.

The present invention belongs to the field of medicine, and specifically discloses an amino alcohol derivative represented by Formula I, a pharmaceutically acceptable salt, solvate, polymorph or prodrug thereof. In addition, the present invention also discloses a pharmaceutical composition comprising the above substances, and a use of the substance in the preparation of a medicament for the prevention and treatment of an immune inflammatory disease, or a disease or condition associated with immunological competence such as multiple sclerosis, ALS, CIDP, systemic lupus erythematosus, rheumatoid arthritis, ulcerative colitis, psoriasis, polymyositis, etc.

The invention relates to the field of biological medicine, and provides an anti-LAP monoclonal antibody or an antigen binding fragment thereof, and the anti-LAP monoclonal antibody comprises heavy chain variable regions HCDR1, HCDR2 and HCDR3 and light chain variable regions LCDR1, LCDR2 and LCDR3. The anti-LAP monoclonal antibody provided by the invention inhibits release of TGF beta1 from the source, deletes inhibitory T cells and improves tumor immune response, can be combined with various immunotherapy drugs for application, can be expanded to more types of cancers, autoimmune diseases and fibrosis diseases, and has huge clinical requirements and huge market potential; the cancers are selected from non-small cell lung cancer, colorectal cancer, pancreatic cancer, kidney cancer, gastric cancer, liver cancer, ovarian cancer, breast cancer, melanoma or glioma; the fibrosis diseases comprise pulmonary fibrosis or hepatic fibrosis; and the autoimmune diseases are selected from systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, dermatomyositis, polymyositis, vasculitis or xerosis.

The invention relates to the use of an inhibitor of the dihydrofolate reductase enzyme selected from the group that consists of methotrexate, trimetrexate and pemetrexed; or a pharmaceutically acceptable salt thereof, for the preparation of a drug for the treatment or prevention of recurrences of a disease selected from the group that consists of cancer, psoriasis, psoriatic arthritis, juvenile polyarticular arthritis, rheumatoid arthritis, Crohn's disease, polymyositis, dermatomyositis and sarcoidosis, wherein said treatment or prevention includes administering to a patient, simultaneously, separately or sequentially, a lipophilic statin and the inhibitor of the dihydrofolate reductase enzyme. The invention also relates to a pharmaceutical composition which includes the inhibitor of the dihydrofolate reductase enzyme and the lipophilic statin together with pharmaceutically acceptable carriers and/or vehicles.